{"id":6947,"date":"2005-12-13T15:16:54","date_gmt":"2005-12-13T14:16:54","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=6947"},"modified":"2014-05-21T16:37:00","modified_gmt":"2014-05-21T16:37:00","slug":"american-association-for-the-study-of-liver-diseases-aasld-november-11-15-2005-san-francisco","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/6947","title":{"rendered":"American Association For The Study of Liver Diseases (AASLD),  November 11-15, 2005 San Francisco"},"content":{"rendered":"<p><strong>A wide range of reports form the AASLD conference are online on the NATAP.org website:<\/strong><\/p>\n<p>National AIDS Treatment Advocacy Project &#8211; NATAP<br \/>\n<a href=\"http:\/\/www.natap.org\">http:\/\/www.natap.org<\/a><\/p>\n<p>American Association for the Study of Liver Diseases\u00a0November 11-15, 2005 San Francisco<br \/>\n<a href=\"http:\/\/www.natap.org\/2005\/AASLD\/aasld.htm\">http:\/\/www.natap.org\/2005\/AASLD\/aasld.htm<\/a><\/p>\n<p>Reports include studies of new treatments, transplantation and monitoring fibrosis in liver disease:<\/p>\n<ul>\n<li>Consensus Interferon: study results at AASLD<\/li>\n<li>Albuferon-Alpha (Albumin-Interferon Alpha) (11\/17\/05)<\/li>\n<li>REPEAT Study: Non-responders to =12 weeks\u0092 treatment with standard-dose pegylated interferon alfa-2b (PegIntron) plus ribavirin received standard dose of Pegasys + ribavrin or double dose Pegasys + ribavirin (11\/15\/05)<\/li>\n<li>Albuferon + ribavirin in PegIFN non-responders: phase 2 study (11\/15\/05)<\/li>\n<li>SCH 503034 HCV protease inhibitor monotherapy in HCV genotype 1 IFN non-responders (11\/15\/05)<\/li>\n<li>VX-950 hepatitis C Protease inhibitor (11\/15\/05)<\/li>\n<li>Combination therapy with SCH-503034 HCV protease inhibitor &amp; PegIntron in non-responders: phase 1b study results (11\/15\/05)<\/li>\n<li>Performance of APRI for the diagnosis of significant hepatic fibrosis is improved by a simple modification (11\/14\/05)<\/li>\n<li>Long term results after therapy with pegylated interferon alpha-2a (Pegysys) in HCV-positive liver transplant recipients.<\/li>\n<li>Predicting outcome in patients with HCV after organ liver transplant: a 15-year follow-up. (11\/14\/05)<\/li>\n<li>Recurrent hepatitis C is a risk factor for poor outcome after liver retransplantation. (11\/14\/05)<\/li>\n<li>Multicentred randomised trial of HCV treatment with PegInterferon-alpha 2a (Pegasys) and ribavirin after liver transplantation: one year report (11\/14\/05)<\/li>\n<li>On treatment virological response of 70% in 100 patients treated with combination antiviral therapy for recurrent HCV following liver transplantation. (11\/14\/05)<\/li>\n<li>Is liver biopsy justified in hepatitis C genotype 2 and 3? (11\/14\/05)<\/li>\n<li>Fibroscan, monitoring liver stiffness: a new tool to measure liver fibrosis during therapy. (11\/14\/05)<\/li>\n<li>Telbivudine (LdT) Phase 3 One Year Study Results (11\/14\/05)<\/li>\n<li>Liver Cancer developed Among SVRs; Sexual Dysfunction among HCV+ (11\/14\/05)<\/li>\n<li>Virological and histological features of HCV in patients with normal ALT: results of a ten year prospective follow-up study. (11\/14\/05)<\/li>\n<li>African-American patients had fewer office visits and were less likely to return for a second office visit (11\/14\/05)<\/li>\n<li>Coffee drinking decreases the risk of chronic liver disease in the US population. (11\/14\/05)<\/li>\n<li>Impact of caffeine consumption on ALT and histological activity in patients with chronic active HCV. (11\/14\/05)<\/li>\n<li>Troglitazone significantly reduced tumor growth in vivo, and caused tumor regression in liver cells (11\/14\/05)<\/li>\n<li>Study evaluations of non-invasive fibrosis tests (11\/14\/05)<\/li>\n<li>Liver histology in hepatitis C patients with normal ALT levels. (11\/14\/05)<\/li>\n<li>Hispanics developed cirrhosis more quickly due to the presence of fatty liver &amp; diabetes (11\/14\/05)<\/li>\n<li>Cannabinoids block interferon-mediated suppression of hepatitis C virus (HCV) replication. (11\/14\/05)<\/li>\n<li>Cryoblobinemia is associated with steatosis and fibrosis in chronic HCV. (11\/14\/05)<\/li>\n<li>Independent validation and comparison with fibroscan, fibrotest and liver biopsy of clinical glycomics for the non invasive assessment of liver fibrosis in chronic HCV. (11\/14\/05)<\/li>\n<li>New hepatitis C polymerase inhibitor HCV-796 study in patients &#8211; (11\/11\/05)<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>A wide range of reports form the AASLD conference are online on the NATAP.org website: National AIDS Treatment Advocacy Project &#8211; NATAP http:\/\/www.natap.org American Association for the Study of Liver Diseases\u00a0November 11-15, 2005 San Francisco http:\/\/www.natap.org\/2005\/AASLD\/aasld.htm Reports include studies of &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[30],"tags":[],"class_list":["post-6947","post","type-post","status-publish","format-standard","hentry","category-on-the-web"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/6947","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=6947"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/6947\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=6947"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=6947"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=6947"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}